Sugammadex in end-stage renal disease: too early for a "free-pass"
- PMID: 33200322
- DOI: 10.1007/s12630-020-01860-9
Sugammadex in end-stage renal disease: too early for a "free-pass"
Comment in
-
In reply: Sugammadex in end-stage renal disease: too early for a "free-pass".Can J Anaesth. 2021 Feb;68(2):266-267. doi: 10.1007/s12630-020-01861-8. Epub 2020 Nov 18. Can J Anaesth. 2021. PMID: 33210221 No abstract available.
Comment on
-
Sugammadex use in patients with end-stage renal disease: a historical cohort study.Can J Anaesth. 2020 Dec;67(12):1789-1797. doi: 10.1007/s12630-020-01812-3. Epub 2020 Sep 18. Can J Anaesth. 2020. PMID: 32949009 English.
References
-
- Paredes S, Porter SB, Porter IE 2nd, Renew JR. Sugammadex use in patients with end-stage renal disease: a historical cohort study. Can J Anesth 2020; DOI: https://doi.org/10.1007/s12630-020-01812-3 . - DOI - PubMed
-
- Kapoor MC. Cardiovascular adverse effects of sugammadex. J Anaesthesiol Clin Pharmacol 2020; DOI: https://doi.org/10.4103/joacp.JOACP_132_20 . - DOI - PubMed - PMC
-
- Farkas JD, Long B, Koyfman A, Menson K. BRASH syndrome: bradycardia, renal failure, AV blockade, shock, and hyperkalemia. J Emerg Med 2020; 59: 216-23. - DOI
-
- Naguib M, Brull SJ, Kopman AF, et al. Consensus statement on perioperative use of neuromuscular monitoring. Anesth Analg 2018; 127: 71-80. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
